OncoCyte Co. (NASDAQ:OCX – Get Free Report) major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the transaction, the insider now owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
OncoCyte Stock Up 1.0 %
OncoCyte stock opened at $3.04 on Wednesday. OncoCyte Co. has a 1-year low of $2.08 and a 1-year high of $4.34. The firm’s 50 day simple moving average is $3.07 and its 200 day simple moving average is $2.93.
OncoCyte (NASDAQ:OCX – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. The firm had revenue of $0.10 million during the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.
Analyst Ratings Changes
Read Our Latest Research Report on OncoCyte
About OncoCyte
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Read More
- Five stocks we like better than OncoCyte
- Health Care Stocks Explained: Why You Might Want to Invest
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What is the Australian Securities Exchange (ASX)
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- What is the Euro STOXX 50 Index?
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.